Evidence for Dietary Agmatine Sulfate Effectiveness in Neuropathies Associated with Painful Small Fiber Neuropathy. A Pilot Open-Label Consecutive Case Series Study

Michael L Rosenberg, Vahid Tohidi, Karna Sherwood, Sujoy Gayen, Rosina Medel, Gad M Gilad, Michael L Rosenberg, Vahid Tohidi, Karna Sherwood, Sujoy Gayen, Rosina Medel, Gad M Gilad

Abstract

Peripheral neuropathies associated with painful small fiber neuropathy (SFN) are complex conditions, resistant to treatment with conventional medications. Previous clinical studies strongly support the use of dietary agmatine as a safe and effective treatment for neuropathic pain. Based on this evidence, we conducted an open-label consecutive case series study to evaluate the effectiveness of agmatine in neuropathies associated with painful SFN (Study Registry: ClinicalTrials.gov, System Identifier: NCT01524666). Participants diagnosed with painful SFN and autonomic dysfunctions were treated with 2.67 g/day agmatine sulfate (AgmaSet® capsules containing G-Agmatine® brand of agmatine sulfate) for a period of 2 months. Before the beginning (baseline) and at the end of the treatment period, participants answered the established 12-item neuropathic pain questionnaire specifically developed to distinguish symptoms associated with neuropathy and to quantify their severity. Secondary outcomes included other treatment options and a safety assessment. Twelve patients were recruited, and 11 patients-8 diagnosed with diabetic neuropathy, two with idiopathic neuropathy and one with inflammatory neuropathy-completed the study. All patients showed improvement in neuropathic pain to a varied extent. The average decrease in pain intensity was 26.0 rating points, corresponding to a 46.4% reduction in overall pain (p < 0.00001). The results suggest that dietary agmatine sulfate has a significant effect in reducing neuropathic pain intensity associated with painful SFN resistant to treatment with conventional neuropathic pain medications. Larger randomized placebo-controlled studies are expected to establish agmatine sulfate as a preferred treatment.

Keywords: agmatine; neuropathic pain; neuropathies; peripheral neuropathy; small fiber neuropathy.

Conflict of interest statement

Gad M. Gilad is a patent co-owner of products related to the present work and stockholder in Gilad&Gilad LLC. Other coauthors declare no conflict of interest.

References

    1. Dahlhamer J., Lucas J., Zelaya C., Nahin R., Mackey S., DeBar L., Kerns R., Von Korff M., Porter L., Helmick C. Prevalence of chronic pain and high-impact chronic pain among adults—United States, 2016. MMWR Morb. Mortal. Wkly. Rep. 2018;67:1001–1006. doi: 10.15585/mmwr.mm6736a2.
    1. DiBonaventura M.D., Sadosky A., Concialdi K., Hopps M., Kudel I., Parsons B., Cappelleri J.C., Hlavacek P., Alexander A.H., Stacey B.R., et al. The prevalence of probable neuropathic pain in the US: Results from a multimodal general-population health survey. J. Pain Res. 2017;10:2525–2538. doi: 10.2147/JPR.S127014.
    1. Levine T.D. Small fiber neuropathy: Disease classification beyond pain and burning. J. Cent. Nerv. Syst. Dis. 2018;10:1–6. doi: 10.1177/1179573518771703.
    1. Finnerup N.B., Attal N., Haroutounian S., McNicol E., Baron R., Dworkin R.H., Gilron I., Haanpää M., Hansson P., Jensen T.S., et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 2015;14:162–173. doi: 10.1016/S1474-4422(14)70251-0.
    1. Meng W., Deshmukh H.A., van Zuydam N.R., Liu Y., Donnelly L.A., Zhou K., Wellcome Trust Case Control Consortium 2 (WTCCC2) Surrogate Markers for Micro- and Macro-Vascular Hard Endpoints for Innovative Diabetes Tools (SUMMIT) Study Group. Morris A.D., Colhoun H.M., et al. A genome-wide association study suggests an association of Chr8p21.3 (GFRA2) with diabetic neuropathic pain. Eur. J. Pain. 2015;19:392–399. doi: 10.1002/ejp.560.
    1. Binder A., Baron R. The pharmacological therapy of chronic neuropathic pain. Dtsch. Arztebl. Int. 2016;113:616–625. doi: 10.3238/arztebl.2016.0616.
    1. Gilron I., Baron R., Jensen T. Neuropathic pain: Principles of diagnosis and treatment. Mayo Clin. Proc. 2015;90:532–545. doi: 10.1016/j.mayocp.2015.01.018.
    1. Chiang M.C., Tseng M.T., Pan C.L., Chao C.C., Hsieh S.T. Progress in the treatment of small fiber peripheral neuropathy. Expert Rev. Neurother. 2015;15:305–313. doi: 10.1586/14737175.2015.1013097.
    1. Brouwer B.A., de Greef B.T., Hoeijmakers J.G., Geerts M., van Kleef M., Merkies I.S., Faber C.G. Neuropathic pain due to small fiber neuropathy in aging: Current management and future prospects. Drugs Aging. 2015;32:611–621. doi: 10.1007/s40266-015-0283-8.
    1. Freynhagen R., Bennett M.I. Diagnosis and management of neuropathic pain. Brit. Med. J. 2009;339:b3002. doi: 10.1136/bmj.b3002.
    1. Yang M., Qian C., Liu Y. Suboptimal treatment of Diabetic Peripheral Neuropathic Pain in the United States. Pain Med. 2015;16:2075–2083. doi: 10.1111/pme.12845.
    1. Goodman C.W., Brett A.S. Gabapentin and Pregabalin for pain—Is increased prescribing a cause for concern? N. Engl. J. Med. 2017;377:411–414. doi: 10.1056/NEJMp1704633.
    1. Xi-Ding Y., Ping-Fei F., Da-Xiong X., Yong-Yu Y. Topical treatments for diabetic neuropathic pain. Exp. Ther. Med. 2019;17:1963–1976. doi: 10.3892/etm.2019.7173.
    1. Volkow N.D., Koroshetz W. Lack of evidence for benefit from long-term use of opioid analgesics for patients with neuropathy. JAMA Neurol. 2017;74:761–762. doi: 10.1001/jamaneurol.2017.0466.
    1. Irving G., Tanenberg R.J., Raskin J., Risser R.C., Malcolm S. Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain. Int. J. Clin. Pract. 2014;68:1130–1140. doi: 10.1111/ijcp.12452.
    1. Oaklander A.L., Nolano M. Scientific Advances in and Clinical Approaches to Small-Fiber Polyneuropathy: A Review. JAMA Neurol. 2019;76:1240–1251. doi: 10.1001/jamaneurol.2019.2917.
    1. Gilad G.M., Salame K., Rabey J.M., Gilad V.H. Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci. 1995;58:PL41–PL46. doi: 10.1016/0024-3205(95)02274-0.
    1. Xu W., Gao L., Li T., Shao A., Zhang J. Neuroprotective Role of Agmatine in Neurological Diseases. Curr. Neuropharmacol. 2018;16:1296–1305. doi: 10.2174/1570159X15666170808120633.
    1. Kotagale N.R., Taksande B.G., Inamdar N.N. Neuroprotective offerings by agmatine. Neurotoxicology. 2019;73:228–245. doi: 10.1016/j.neuro.2019.05.001.
    1. Piletz J.E., Aricioglu F., Cheng J.-T., Fairbanks C.A., Gilad V.H., Haenisch B., Halaris A., Hong S., Lee J.U., Li J., et al. Agmatine: Clinical applications after 100 years in translation. Drug Discov. Today. 2013;18:880–893. doi: 10.1016/j.drudis.2013.05.017.
    1. Neis V.B., Rosa P.B., Olescowicz G., Rodrigues A.L.S. Therapeutic potential of agmatine for CNS disorders. Neurochem. Int. 2017;108:318–331. doi: 10.1016/j.neuint.2017.05.006.
    1. Gilad G.M., Gilad V.H. Long-Term (5 Years), High Daily Dosage of Dietary Agmatine—Evidence of Safety: A Case Report. J. Med. Food. 2014;17:1–4. doi: 10.1089/jmf.2014.0026.
    1. Keynan O., Mirovsky Y., Dekel S., Gilad V.H., Gilad G.M. Safety and efficacy of dietary agmatine sulfate in lumbar disc-associated radiculopathy. an open-label, dose-escalating study followed by a randomized, double-blind, placebo-controlled trial. Pain Med. 2010;11:356–368. doi: 10.1111/j.1526-4637.2010.00808.x.
    1. Galgano F., Caruso M., Condelli N., Favati F. Focused review: Agmatine in fermented foods. Front. Microbiol. 2012;7:199. doi: 10.3389/fmicb.2012.00199.
    1. Molderings G.J., Heinen A., Menzel S., Lubbecke F., Homann J., Gothert M. Gastrointestinal uptake of agmatine: Distribution in tissues and organs and pathophysiologic relevance. Ann. N. Y. Acad. Sci. 2003;1009:44–51. doi: 10.1196/annals.1304.005.
    1. Haenisch B., von Kügelgen I., Bönisch H., Göthert M., Sauerbruch T., Schepke M., Marklein G., Höfling K., Schröder D., Molderings G.J. Regulatory mechanisms underlying agmatine homeostasis in humans. Am. J. Physiol. Gastrointest. Liver Physiol. 2008;295:G1104–G1110. doi: 10.1152/ajpgi.90374.2008.
    1. Huisman H., Wynveen P., Nichkova M., Kellermann G. Novel ELISAs for screening of the biogenic amines GABA, glycine, beta-phenylethylamine, agmatine, and taurine using one derivatization procedure of whole urine samples. Anal. Chem. 2010;82:6526–6533. doi: 10.1021/ac100858u.
    1. Gilad G.M., Gilad V.H., Rabey J.M. Arginine and ornithine decarboxylation in rodent brain; coincidental changes during development and after ischemia. Neurosci. Lett. 1996;216:33–36. doi: 10.1016/0304-3940(96)12996-7.
    1. Satriano J., Schwartz D., Ishizuka S., Lortie M.J., Thomson S.C., Gabbai F., Kelly J., Blantz R.C. Suppression of inducible nitric oxide generation by agmatine aldehyde: Beneficial effects in sepsis. J. Cell Physiol. 2001;188:313–320. doi: 10.1002/jcp.1119.
    1. Bhagvat K., Blaschko H., Richter D. Amine oxidase. Biochem. J. 1939;33:1338–1341. doi: 10.1042/bj0331338.
    1. Taylor S.L., Leiber E.R. In vitro inhibition of rat intestinal histamine-metabolizing enzymes. Food Cosmetics Toxicol. 1979;17:237–240. doi: 10.1016/0015-6264(79)90287-6.
    1. Lauria G., Lombardi R. Skin biopsy: A new tool for diagnosing peripheral neuropathy. Br. Med. J. 2007;334:1159–1162. doi: 10.1136/.
    1. Low P.A., Caskey P.E., Tuck R.R., Fealey R.D., Dyck P.J. Quantitative sudomotor axon reflex test in normal and neuropathic subjects. Ann. Neurol. 1983;14:573–580. doi: 10.1002/ana.410140513.
    1. Namer B., Pfeffer S., Handwerker H.O., Schmelz M., Bickel A. Axon reflex flare and quantitative sudomotor axon reflex contribute in the diagnosis of small fiber neuropathy. Muscle Nerve. 2013;47:357–363. doi: 10.1002/mus.23543.
    1. Thaisetthawatkul P., Fernandes Filho J.A., Herrmann D.N. Contribution of QSART to the diagnosis of small fiber neuropathy. Muscle Nerve. 2013;48:883–888. doi: 10.1002/mus.23891.
    1. Krause S.J., Backonja M.-M. Development of a Neuropathic Pain Questionnaire. Clin. J. Pain. 2003;19:306–314. doi: 10.1097/00002508-200309000-00004.
    1. Backonja M.-M., Krause S.J. Neuropathic Pain Questionnaire—Short Form. Clin. J. Pain. 2003;19:315–316. doi: 10.1097/00002508-200309000-00005.
    1. Sopacua M., Hoeijmakers J.G.J., Merkies I.S.J., Lauria G., Waxman S.G., Faber C.G. Small-fiber neuropathy: Expanding the clinical pain universe. J. Peripher. Nerv. Syst. 2019;24:19–33. doi: 10.1111/jns.12298.
    1. Shopsin B. The clinical antidepresant effect of exogenous agmatine is not reversed by parachlorophenylalanine: A pilot study. Acta Neuropsychiatr. 2013;25:113–118. doi: 10.1111/j.1601-5215.2012.00675.x.
    1. Piletz J.E., May P.J., Wang G., Zhu H. Agmatine crosses the blood-brain barrier. Ann. N. Y. Acad. Sci. 2003;1009:64–74. doi: 10.1196/annals.1304.007.
    1. Meacham K., Shepherd A., Mohapatra D.P., Haroutounian S. Neuropathic pain: Central vs. peripheral mechanisms. Curr. Pain Headache Rep. 2017;21:28–39. doi: 10.1007/s11916-017-0629-5.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren